A 46-year-old man is currently enrolled in a Phase 2 study of a drug for severe diabetic neuropathy. While the study is on-going
, a new drug becomes commercially available that may have equal or greater benefit to the subject. The investigator should do which of the following? (A) Tell the subject about the new drug but discourage him from switching treatment until the study is completed.
(B) Withhold this information to avoid confusing the subject with other treatment options or alternatives.
(C) Give the subject comprehensive information about the new drug, including its side effects, discuss the pros and cons of both investigational drug and commercially available drug and then allow the subject to decide whether to withdraw from the research to take the new drug.
(D) Dont tell the subject about the new drug since phycian have the right to try our new treatments with their new patients.
The investigator should give the subject comprehensive information about the new drug, including its side effects, discuss the pros and cons of both investigational drug and commercially available drug and then allow the subject to decide whether to withdraw from the research to take the new drug.
It is subject's will that he would either take that research treatment or would try the new treatment, but it is the investigator's duty to tell the subject all about the new drug, about its side effects and benefits, its costs and all other benefits or drawbacks.
(C) Give the subject comprehensive information about the new drug, including its side effects, discuss the pros and cons of both investigational drug and commercially available drug and then allow the subject to decide whether to withdraw from the research to take the new drug.
Explanation:
Whenever a study is done the researcher must follow ethical and moral values and always value the health and health of the study participants. In the case shown in the question above, the study participant has a serious illness and is testing the effects of a drug being produced by the researcher. When a new drug appears that may have the same or better effects than the one being produced, the researcher must be ethical and act to allow the well-being of the study participant. For this reason, the researcher should provide the participant with comprehensive information about the new drug, including its side effects, discuss the pros and cons of the experimental drug and the commercially available drug, and allow the participant to decide whether or not to withdraw from the research for further research. take the new medicine.
He needs to get in contact with the Children’s Bureau (CB). The CB has programs for foster care that “provide board and care payments to eligible children to be placed in foster family homes”. If he has observed that the functioning of this program is inefficient on his region then he needs to reach out the CB to see what changes could be done to better the programs. They could do a research of what has been happening and why it's failing.
Strain is known to be an injury that affects the muscle or tendon by causing twist or tear of a tendon or muscles. Thus, strain can either be complete or partial tear of the muscles or tendon or simple overstretch of the tendon or muscle. Furthermore, strain can be classified as chronic or acute strain.
